Cellectis Announces Development Plans for Eti-cel in r/r NHL
Cellectis, a clinical-stage biotechnology company, is making significant strides in its journey to transform cancer therapies. At a recent major medical conference, the company presented the latest encouraging results from its Phase 1 clinical trial regarding Eti-cel, an innovative treatment for patients with relapsed or refractory non-Hodgkin lymphoma (r/r NHL).
Promising Results from Phase 1 Trials
The company reported an impressive overall response rate (ORR) of 88% and a complete response (CR) rate of 63% from the initial cohort of patients treated with Eti-cel. These specific figures were derived from a group of patients who had undergone at least two prior lines of therapy. These results highlight the potential effectiveness of Eti-cel in this challenging patient population.
Innovative Approach with Dual CAR-T Therapy
Eti-cel is distinguished as the first allogeneic dual CAR-T cell therapy designed to target both CD20 and CD22 simultaneously. This innovative approach marks a significant step forward in treatment strategies for r/r NHL, specifically for patients who have seen little success from existing therapies.
Future Developments and Research Directions
In addition to the positive preliminary outcomes, Cellectis revealed plans to explore the addition of low-dose interleukin-2 (IL-2) support in future trials. Preliminary data suggested that IL-2 could enhance CAR-T cell expansion and persistence, potentially deepening the already impressive response rates seen with Eti-cel.
Next Steps for Patient Recruitment
As part of their ongoing development, Cellectis aims to initiate patient recruitment for its IL-2 cohort in the early part of 2026. They anticipate that comprehensive data from this cohort will be available later in the same year, which could provide deeper insights into the benefits of combining Eti-cel with IL-2 treatment.
About Cellectis and its Mission
Cellectis is committed to pioneering cell and gene therapies that can reshape the landscape of cancer treatment. Their goal is to create off-the-shelf, ready-to-use treatments that address patients' challenges head-on. By leveraging its proprietary gene-editing platform, the company is positioned as a leader in this transformative space within oncology.
Global Footprint and Future Vision
Headquartered in Paris, Cellectis also maintains facilities in the U.S., specifically in New York and Raleigh. The company’s prowess in controlling the entire gene-editing process—from development to manufacturing—places it among the few end-to-end gene therapy companies globally. This comprehensive control is critical in ensuring the safety and effectiveness of their pioneering treatments.
Frequently Asked Questions
What is Eti-cel?
Eti-cel is a dual CAR-T cell therapy developed by Cellectis to target CD20 and CD22 proteins in patients with non-Hodgkin lymphoma.
What were the latest results from the Phase 1 trial?
The latest results showed an overall response rate of 88% and a complete response rate of 63% from initial patients treated.
What is the significance of IL-2 support?
IL-2 is expected to enhance CAR-T cell expansion and persistence, potentially increasing the treatment's effectiveness.
When will Cellectis start patient recruitment for the IL-2 cohort?
Cellectis plans to begin recruiting patients for the IL-2 cohort in the first quarter of 2026.
How does Cellectis ensure quality in its therapies?
Cellectis maintains end-to-end control over its gene-editing process, which is crucial for the development and safety of its therapies.
